Vesicular stomatitis virus–based Ebola vaccines with improved cross-protective efficacy
Abstract For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Cô te d'Ivoire,
and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed …
and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed …
Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus
D Matassov, A Marzi, T Latham, R Xu… - The Journal of …, 2015 - academic.oup.com
Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing
Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of …
Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of …
Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV)
glycoprotein (GP)(rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic …
glycoprotein (GP)(rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic …
Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
G Wong, J Audet, L Fernando, H Fausther-Bovendo… - Vaccine, 2014 - Elsevier
Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to
90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a …
90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a …
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
CE Mire, JB Geisbert, A Marzi, KN Agans… - PLoS neglected …, 2013 - journals.plos.org
Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and
nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for …
nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for …
The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
E Suder, W Furuyama, H Feldmann… - Human vaccines & …, 2018 - Taylor & Francis
The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …
progress of several vaccines and antivirals through clinical trials, including the replication …
Single immunization with a monovalent vesicular stomatitis virus–based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo …
D Falzarano, F Feldmann, A Grolla… - The Journal of …, 2011 - academic.oup.com
The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform
expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal …
expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal …
Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice
NJ Lennemann, AS Herbert, R Brouillette… - Journal of …, 2017 - Am Soc Microbiol
The recent Ebola virus (EBOV) epidemic in West Africa demonstrates the potential for a
significant public health burden caused by filoviral infections. No vaccine or antiviral is …
significant public health burden caused by filoviral infections. No vaccine or antiviral is …
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
TW Geisbert, KM Daddario-DiCaprio, MG Lewis… - PLoS …, 2008 - journals.plos.org
Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as
an emerging/re-emerging virus and as a potential biological weapon. Substantial progress …
an emerging/re-emerging virus and as a potential biological weapon. Substantial progress …
Detectable Vesicular Stomatitis Virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans
JH Poetsch, C Dahlke, ME Zinser… - The Journal of …, 2019 - academic.oup.com
In response to the Ebola virus (EBOV) crisis of 2013–2016, a recombinant vesicular
stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single …
stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single …